Glutathione

Glutathione has been given to people in a handful of small controlled trials, and nearly all of them gave it by mouth. Their results do not agree. A six-month randomized trial in 54 healthy non-smoking adults found that oral glutathione raised glutathione levels in whole blood, red cells, plasma, lymphocytes and cheek cells. A four-week randomized trial in 40 healthy adults found no change in glutathione status or in two urinary markers of oxidative damage. A 2026 pilot in 14 adults compared how well three oral forms were absorbed over a single day.

Every endpoint in those trials was a level or a marker measured in blood, urine or cells. None of them tested whether anyone recovered faster, trained better, got sick less often, or looked different.

The intravenous drip has no controlled trial among the cited sources at all. What the record does hold for IV glutathione is an FDA alert about eight patients who reacted to infusions compounded from supplement-grade powder contaminated with bacterial endotoxin, two of whom ended up in hospital.

Glutathione is a tripeptide, three amino acids long: glutamate, cysteine and glycine. It is the most abundant small thiol molecule in animal cells, and together with its oxidized partner, glutathione disulfide, it forms the main redox pair cells use to manage oxidative load.

Your cells make it themselves, in two enzyme steps. That matters for reading the research, because there are two very different kinds of glutathione study. Some measure the body's own glutathione and how it changes with age, diet or disease. Others give people glutathione, or its raw materials, and see what happens. Only the second kind says anything about taking it.

What It Does Inside Cells

Glutathione's jobs reach well past mopping up free radicals. The 2004 Journal of Nutrition review in the source list credits it with roles in antioxidant defense, nutrient metabolism, and the regulation of gene expression, DNA and protein synthesis, cell proliferation and death, signal transduction, cytokine production and immune response, plus a chemical tagging process called protein glutathionylation. The same review links glutathione deficiency to oxidative stress, and oxidative stress to aging and a long list of diseases. Those are associations involving the body's own supply.

Why the Supply Is Set by Cysteine

Production is limited mainly by the activity of the first enzyme in the pathway, gamma-glutamylcysteine synthetase, and by how much cysteine is available, with glutathione itself throttling its own synthesis through feedback. Adequate protein intake is needed to keep levels steady, and cysteine sources such as N-acetylcysteine and methionine work as precursors for tissue glutathione. Feeding the pathway is a separate strategy from swallowing the finished molecule.

The Problem With Swallowing It

Taken orally, glutathione has to survive the gut, where an intestinal enzyme, gamma-glutamyl transpeptidase, breaks it down. The authors of the 2026 absorption study describe the typical result as only modest increases in blood levels. Before the 2015 six-month trial, oral glutathione had been shown to be bioavailable in laboratory animals, and its effectiveness in humans had not been established. That gap is why the human trials below measured levels first.

The overreach with glutathione mostly comes from treating one route, one marker or one molecule as if it stood for all the others.

Oral data does not cover the drip. The trials that raised blood levels gave glutathione by mouth. The trial that compared absorption tested three oral capsules. None of it says what an IV push does, and the IV route arrives with its own risks, covered under safety. Citing oral bioavailability to sell infusions borrows evidence from the wrong route.

A higher level is not a benefit. The 2015 trial showed oral glutathione can raise stores in blood and cells over months, which settled an open question. It did not show anyone was healthier for it, and the levels fell back to baseline within a month of stopping. The doubling of natural killer cell activity is an immune measurement in a subset of participants, not fewer infections.

The oral trials disagree. A four-week trial in 40 healthy adults found no movement in glutathione status or in oxidative-damage markers. The six-month trial found both levels and the oxidized ratio moving. They differed in length and size, and two small trials pointing in different directions is not a settled result.

Absorption figures are not effects. The micellar form's fourfold advantage is a 24-hour blood curve in 14 people, from a study whose authors say functional antioxidant endpoints and longer-term outcomes were not measured, with product and authorship ties to the company that makes it. The liposomal comparator was never formally tested against standard glutathione, so it gives no basis for calling liposomal forms superior.

Precursor results belong to the precursors. The glycine and N-acetylcysteine trial is the most interesting human result in the source list, and it did not give anyone glutathione. Quoting its gait-speed or mitochondrial findings on behalf of a glutathione capsule or drip moves the result onto a product that was never tested.

Low levels in disease are not a treatment target by default. The body's own glutathione is reduced in many conditions. That association, drawn from measuring endogenous glutathione, does not show that adding glutathione from outside changes how those diseases go.

Oral glutathione has short and small safety data. In the 2026 study, 14 healthy adults took the micellar form daily for 30 days in a single-arm follow-up, and liver enzymes (ALT, AST, ALP), creatinine, electrolytes and blood counts showed no significant changes. The abstracts of the 2011 and 2015 oral trials do not report adverse-event findings. Nothing in the cited sources covers use beyond six months.

The documented harm is from injection quality. In January 2019 FDA received a report of seven outpatient clinic patients who, within minutes of IV glutathione compounded by a pharmacy, developed nausea, vomiting, lightheadedness, chills, body aches and sneezing. One developed low blood pressure and difficulty breathing and was taken to hospital. A second report described an eighth patient, from a different pharmacy, admitted to hospital with chills, fever and shaking and a possible bloodstream infection. Both pharmacies had used glutathione powder labelled "Caution: Dietary Supplement" whose manufacturer sold it for supplements only. FDA testing found excessive bacterial endotoxin in every sample, some as high as five times the appropriate limit for the dose given. Endotoxin reactions can range from fever to shock and death.

Regulatory status. No FDA-approved product has glutathione as an active ingredient for oral, IV, intramuscular, subcutaneous or nebulised use. FDA lists it in Category 1 for compounding, with no route restriction, meaning it is still under evaluation with no current enforcement intent; that is not approval. WADA does not list glutathione, but its method M2.2 prohibits IV infusions or injections above 100 mL per 12-hour period, and glutathione drips routinely exceed that, so a tested athlete can break the rule through the route even though the substance itself is allowed.

The honest summary is narrower than either the marketing or the dismissal. Glutathione taken by mouth can get past the gut: one six-month controlled trial raised stores measurably, and an absorption pilot showed formulation changes how much reaches the blood. That is a real finding, and it is a finding about levels.

What remains unknown is whether raising those levels in healthy people changes anything they would notice or that a doctor would count. No trial in the source list tested that for glutathione itself. The one trial with functional outcomes used precursors in older adults with measured deficiency, which is a different intervention in a different population.

For the drip, the question is not absorption. It is what is in the bag and who made it, because the only human IV record cited here is an adverse-event investigation.

Not supported as an IV therapy by any cited trial. The controlled human glutathione trials here all used oral capsules. The intravenous record consists of FDA adverse-event reports tied to contaminated compounded injections.

Not an approved medicine for any route. No approved product uses glutathione as the active ingredient for oral, IV, intramuscular, subcutaneous or nebulised use. BSS PLUS, an eye-surgery irrigating solution, contains glutathione disulfide as one of eight components and has no bearing on drips or capsules.

Not interchangeable with its precursors. Glycine and N-acetylcysteine feed the body's own production. Results from giving those two do not transfer to glutathione products, or back.

Not proven to improve recovery, performance, immunity or skin. Those were not endpoints in any cited glutathione trial. Blood levels and urinary markers were.

Glutathione is one of the more frustrating compounds I cover, because the molecule is genuinely important and the drip, the version people ask me about, is the one route with no trial behind it.

I will give the oral data its due. Until 2015 nobody had shown in people that swallowing glutathione raised body stores, and a six-month placebo-controlled trial then showed that they do rise. That deserves to be said plainly. So does the four-week trial that found nothing, and so does the fact that neither one measured anything a person would feel.

Where I stay firm is the drip. When someone cites oral absorption studies to justify an IV bag, they are using evidence from one route to sell another, and the only IV event in the record I trust here is an FDA investigation into endotoxin-contaminated powder that put people in hospital. If glutathione interests you, the more defensible thread in this literature is the body's own production and what feeds it, not the infusion chair.